SCHEMBL7335

SCHEMBL7335

O=[N+]([O-])c1cc(Br)c(F)cc1F

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
ALDH1A1 P00352 3/20 0.48
HIF1A Q16665 1/20 0.48
VCAM1 P19320 1/20 0.46
MAPT P10636 4/20 0.45
PKM P14618 1/20 0.45
ESPL1 Q14674 1/20 0.44
MAPK1 P28482 2/20 0.44
CYP3A4 P08684 1/20 0.42
CTSB P07858 1/20 0.42
VCP P55072 1/20 0.41
CYP1A2 P05177 1/20 0.38
HSPB1 P04792 2/20 0.38
MEN1 O00255 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
TDO2 P48775 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29663529 1.00 ATM (0.55) ATMTDP1ALDH1A1HIF1AVCAM1
SCHEMBL29740055 0.91 ATM (0.55) ATMTDP1ALDH1A1HIF1AVCAM1
SCHEMBL310906 0.91 ATM (0.55) ATMTDP1ALDH1A1HIF1AVCAM1
SCHEMBL18905090 0.89 TDP1 (0.52) ATMTDP1ALDH1A1HIF1AVCAM1
SCHEMBL4397890 0.87 MAPT (0.53) ATMTDP1ALDH1A1HIF1AVCAM1
SCHEMBL30598678 0.87 MAPT (0.53) ATMTDP1ALDH1A1HIF1AVCAM1
SCHEMBL45486 0.84 TDP1 (0.60) ATMTDP1ALDH1A1HIF1AVCAM1
SCHEMBL7759334 0.83 MAPT (0.53) ATMTDP1ALDH1A1HIF1AVCAM1
SCHEMBL744876 0.82 TDP1 (0.46) ATMTDP1ALDH1A1HIF1AMAPT
SCHEMBL601789 0.82 CYP1A2 (0.47) ATMTDP1ALDH1A1HIF1AVCAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637438-B2 Protoporphyrinogen oxidase inhibitors ENKO CHEM, INC. (US) 2026-05-26 US disclosed
EP-4568746-B1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2026-04-29 EP disclosed
US-20260068886-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL OERTH BIO LLC (US) 2026-03-12 US disclosed
US-20260047267-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2026-02-12 US disclosed
US-20260042788-A1 STAT6 COMPOUNDS GILEAD SCIENCES INC (US) 2026-02-12 US disclosed
US-20260042747-A1 KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF ALIVEXIS, INC. (JP) 2026-02-12 US disclosed
US-12453731-B2 Aniline-based WDR5 protein-protein interaction inhibitor, and preparation method and use thereof CHINA PHARMACEUTICAL UNIVERSITY (CN) 2025-10-28 US disclosed
EP-4598927-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Tenvie Therapeutics Inc. (US) 2025-08-13 EP disclosed
EP-4134364-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2025-07-30 EP disclosed
US-20250236617-A1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2025-07-24 US disclosed
US-5977107-A Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonists COCENSYS, INC. (US) 1999-11-02 US disclosed
WO-1999009845-A1 IMIDAZOQUINOXALINE PROTEIN TYROSINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 1999-03-04 WO disclosed
US-5734073-A Halogenation reactions BNFL FLUOROCHEMICALS LTD (GB) 1998-03-31 US disclosed
EP-0784054-A1 1,2,3,4-TETRAHYDROQUINOXALINEDIONE DERIVATIVE YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1997-07-16 EP disclosed
US-5631373-A NERVOUS SYSTEM DISORDERS STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) 1997-05-20 US disclosed
US-5622952-A NERVOUS SYSTEM DISORDERS; ADMINISTERING 1,4-DIHYDROQUINOXALINE-2,3-DIONE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) 1997-04-22 US disclosed
US-5620979-A TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA OR SURGERY STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) 1997-04-15 US disclosed
EP-0732942-A1 ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS ACEA PHARMACEUTICALS, INC. (US) 1996-09-25 EP disclosed
US-5514680-A ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) 1996-05-07 US disclosed
WO-1995012417-A1 ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS ACEA PHARMACEUTICALS, INC. (US) 1995-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042788-A1 STAT6 COMPOUNDS STAT6, IL6ST, NFATC1 ATM 1978/4885TDP1 3845/4885ALDH1A1 1587/4885
US-12637438-B2 Protoporphyrinogen oxidase inhibitors PPOX, CYP4X1, CBR3 ATM 3613/4885TDP1 2308/4885ALDH1A1 741/4885
US-20250236617-A1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES GRIN2C, CYP3A4, BICRA ATM 3598/4885TDP1 2132/4885ALDH1A1 949/4885
US-12453731-B2 Aniline-based WDR5 protein-protein interaction inhibitor, and preparation method and use thereof MLLT1, WDR77, MLLT3 ATM 2397/4885TDP1 2719/4885ALDH1A1 2270/4885
US-20260047267-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES LBR, OXER1, NPY1R ATM 4017/4885TDP1 3369/4885ALDH1A1 2125/4885
US-20260042747-A1 KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF KIT, LTK, HRH3 ATM 2280/4885TDP1 1071/4885ALDH1A1 1295/4885
US-20260068886-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL CRBN, STUB1, CUL1 ATM 1946/4885TDP1 3232/4885ALDH1A1 3713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.